Published on
July 6, 2020
- 06:00 GMT
Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating ...
Following higher than expected effects on steatosis reduction during the Phase IIb NATIVE trial in NASH, the number of patients to be recruited in the trial evaluating lanifibranor in patients with T2DM and NAFLD has been reduced to 34 (vs. 64 initially) …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
...
